BridgeBio Pharma, Inc. (BBIO) Form 10-Q — Aug 10, 2026

$BBIOForm 10-QFiled Aug 10, 2026, 4:31 PM ET0001743881-26-000027Original filing

BridgeBio Pharma reported Q2 2026 total revenues of $243.7 million, more than double the $110.6 million a year earlier, driven by net product revenue of $222.4 million from the Attruby (acoramidis) launch versus $71.5 million in Q2 2025. Net loss narrowed to $155.9 million, or $0.78 per share, from $183.8 million, or $0.95 per share, in the year-ago quarter. The balance sheet shows $677.9 million of cash plus $42.2 million in marketable securities, but the company carries $2.505 billion of convertible notes across four series and $879.4 million of long-term deferred royalty obligations against a total stockholders' deficit of $2.50 billion.

Key figures

Revenue: 243676000
Total Debt: 2505000000
Revenue Yoy: Total revenue +120% YoY ($243.7M vs $110.6M); net product revenue +211% YoY ($222.4M vs $71.5M)
Total Assets: 1217299000
Cash Position: 677911000
Shares Outstanding: 195487474
Pdufa date bbp418: 2026-11-27
Pdufa date encaleret: 2027-05-08
H1 2025 total revenue: 227198000
H1 2026 total revenue: 438191000
Marketable securities: 42249000
Total revenue q2 2025: 110565000
Bbot ownership percent: 18.2
Convertible notes 2027: $550.0M face, 2.50%, due 2027-03-15, classified current
Convertible notes 2029: $747.5M face, 2.25%, due 2029-02-01
Convertible notes 2031: $575.0M face, 1.75%, due 2031-03-01
Convertible notes 2033: $632.5M face, 0.75%, due 2033-02-01
H1 2026 share repurchases: 210003000
Net product revenue q2 2025: 71501000
Net product revenue q2 2026: 222440000
Bbot stake level1 fair value: 111200000
Deferred royalty obligations long term: 879374000
Minimum noncancellable purchase commitments: 158000000
Deferred royalty obligations current portion: 29283000
Noncash interest expense deferred royalties q2 2026: 41345000

Price after filing

1 day: 0.0%7 days: -5.4%30 days: -11.5%

Close on the filing date to close N calendar days later (from $84.48). Historical, not a forecast.

AI analysis

Red flags8 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.